Metrics as of 10/16/2026, 08:51 AM (Berlin time), refresh in progress.
Electra Therapeutics Inc.
Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.
1D
-2.1%
1W
-4.3%
1M
–
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
PRICE TARGET LOW
US$32.00
CONSENSUS
US$32.00
MEDIAN
US$32.00
PRICE TARGET HIGH
US$32.00
No current analyst ratings available.
FREE FLOAT
–
FLOAT SHARES
–
AVG. DAILY VOLUME (30D)
803,551
GORDON CARL L
GORDON CARL L
GORDON CARL L
GORDON CARL L
GORDON CARL L
Electra Therapeutics Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Quehuong Dong, the company employs around 46 people.
The IPO was on 18/09/2026; the stock trades on NASDAQ under the ticker ETRA.
The average price target is US$32.00, ranging from US$32.00 to US$32.00, with a median of US$32.00.
This is an external assessment, not a statement by Market Jury.
No, Electra Therapeutics currently does not pay a dividend.
Clicking "Analyze stock" lets five strategies assess Electra Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.